《欧洲呼吸学会肺泡蛋白沉积症诊断和管理指南》解读  

Interpretation of the European Respiratory Society Guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis

作　　者：徐东[1] 仇丽茹[1] 罗小平[1] 周秀云[1] 黄永建[1] XU Dong;QIU Liru;LUO Xiaoping;ZHOU Xiuyun;HUANG Yongjian(Department of Pediatrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430073,China)

机构地区：[1]华中科技大学同济医学院附属同济医院儿科,武汉430073

出　　处：《医药导报》2024年第12期1869-1873,共5页Herald of Medicine

摘　　要：肺泡蛋白沉积症(PAP)是一种呼吸系统罕见病,为进一步提高临床医生对PAP的认识和诊疗水平,欧洲呼吸学会发布了第一版诊断和管理指南,包括对文献的系统回顾和应用建议、评估、发展和评估分级(GRADE)方法来评估证据的确定性和建议的强度,制定了5个患者、干预、比较、结果(PICO)问题和2个叙述性问题,并给出了相应的建议和循证证据,包括PAP的管理与全肺灌洗,粒细胞-巨噬细胞集落刺激因子(GM-CSF)替代治疗,利妥昔单抗,血浆置换和肺移植。此外,还就GM-CSF抗体检测、支气管肺泡灌洗和肺活检的使用提出了建议。该文就指南的主要建议内容进行综述解读。To improve the understanding of clinicians on the diagnostic criteria and treatment principlis of pulmonary alveolar proteinosis(PAP),which is a rare respiratory disease.European Respiratory Society published the first edition guidelines for PAP,including a systematic review of the literature and the application of the grading of recommendations,assessment,development and evaluation(GRADE)approach to assess the certainty of evidence and the strength of recommendations.Five questions of patient,intervention,comparison,outcome(PICO)and two narrative questions were developed.Recommendations and evidence-based evidence were given,including management of PAP,whole lung lavage,granulocyte-macrophage colony-stimulating factor(GM-CSF)therapy,rituximab,plasma exchange,and lung transplantation.In addition,recommendations were given for the use of GM-CSF antibody testing,bronchoalveolar lavage,and lung biopsy.This study is to interpret the main content of the guideline.

关 键 词：肺泡蛋白沉积症 临床诊断 临床治疗 管理指南 指南解读 

分 类 号：R563[医药卫生—呼吸系统]